152 related articles for article (PubMed ID: 15934956)
1. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism.
González EA; Al-Aly Z; Martin KJ
Semin Dial; 2005; 18(3):171-4. PubMed ID: 15934956
[TBL] [Abstract][Full Text] [Related]
2. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
3. [K/DOQI clinical practice guidelines for bone metabolism and disease in CKD].
Sakaguchi T; Akizawa T
Clin Calcium; 2004 Sep; 14(9):9-14. PubMed ID: 15577103
[TBL] [Abstract][Full Text] [Related]
4. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
Bailie GR; Massry SG;
Pharmacotherapy; 2005 Dec; 25(12):1687-707. PubMed ID: 16305288
[TBL] [Abstract][Full Text] [Related]
5. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
6. [Outlines of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease].
Orita H; Akizawa T
Clin Calcium; 2004 May; 14(5):693-7. PubMed ID: 15577029
[TBL] [Abstract][Full Text] [Related]
7. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
8. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
Ito H; Kinugasa E
Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
[TBL] [Abstract][Full Text] [Related]
9. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
Inaguma D; Tatematsu M
Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
[TBL] [Abstract][Full Text] [Related]
10. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
Yano S
Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
[TBL] [Abstract][Full Text] [Related]
11. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications.
Uribarri J;
Semin Dial; 2004; 17(5):349-50. PubMed ID: 15461740
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
[TBL] [Abstract][Full Text] [Related]
13. The need for better control of secondary hyperparathyroidism.
Locatelli F
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified.
Ix JH; Quarles LD; Chertow GM
Nat Clin Pract Nephrol; 2006 Jun; 2(6):337-9. PubMed ID: 16932455
[TBL] [Abstract][Full Text] [Related]
15. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
Kumar N; Lindberg J; David K; Morris J; Menoyo J
Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
[TBL] [Abstract][Full Text] [Related]
16. Managing bone parameters in dialysis patients: international guideline conflicts.
Faull RJ
Semin Dial; 2007; 20(3):191-4. PubMed ID: 17555479
[TBL] [Abstract][Full Text] [Related]
17. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
[TBL] [Abstract][Full Text] [Related]
18. Mineral metabolism disturbances in patients with chronic kidney disease.
Kestenbaum B; Belozeroff V
Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
[TBL] [Abstract][Full Text] [Related]
19. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
20. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
